How Much Does Dayvigo (Lemborexant) Cost in Michigan in 2026?

Michigan Retail and Cash-Pay Pricing for Dayvigo

The average cash-pay price for a 30-day supply of Dayvigo across Michigan retail pharmacies in 2026 sits near $85, a steep discount from Eisai's $320 list price. That gap exists because pharmacy benefit managers negotiate rebates off the wholesale acquisition cost, and discount platforms like GoodRx or RxSaver pass negotiated rates to uninsured or underinsured patients.

Prices vary by pharmacy. Large chains in metro Detroit and Grand Rapids tend to cluster within $5 to $10 of the $85 average, while independent pharmacies in the Upper Peninsula or rural counties may price slightly higher due to lower dispensing volume. Costco and mail-order pharmacies sometimes undercut brick-and-mortar prices by 10% to 15%, making them worth checking if you have flexibility.

Cash-pay pricing applies when a patient either lacks prescription drug coverage entirely or chooses not to run the claim through insurance (for example, when the insurer's negotiated price exceeds a discount card's rate). Always ask the pharmacist to compare your insurance copay against the cash-pay price before filling. This is a quick check that can save $20 to $50 on a single fill.

Lemborexant received FDA approval in December 2019 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults [1]. The SUNRISE-1 trial (N=1,006), published in JAMA Network Open, demonstrated that lemborexant 5 mg and 10 mg significantly improved objective sleep onset latency versus placebo at one month, with the 10 mg dose reducing latency by a mean of 10.7 minutes more than placebo (P<0.001) [2]. That efficacy profile is part of why payers have gradually expanded formulary placement for DORAs over the past several years.

Michigan Medicaid Coverage for Lemborexant

Michigan Medicaid covers Dayvigo, but a prior authorization (PA) is required before the state will reimburse the claim. The PA process exists because Medicaid preferred drug lists (PDLs) generally favor lower-cost generic sleep aids as first-step therapy.

To obtain PA approval, prescribers typically need to document one of the following: a trial and failure of (or contraindication to) a generic sedative-hypnotic such as zolpidem or trazodone, a clinical rationale for selecting a DORA mechanism over GABA-A agonists, or a diagnosis where the patient's comorbidity profile makes traditional hypnotics inappropriate (e.g., history of complex sleep behaviors on Z-drugs, substance use disorder risk, or concurrent benzodiazepine taper). The Michigan Department of Health and Human Services (MDHHS) pharmacy benefit team reviews PA requests, and turnaround is generally 24 to 72 hours for standard requests.

If a PA is denied, the prescriber can file a clinical appeal. The American Academy of Sleep Medicine (AASM) clinical practice guideline on pharmacologic treatment of chronic insomnia, published in the Journal of Clinical Sleep Medicine, lists suvorexant (another DORA) among recommended medications and acknowledges the orexin receptor antagonist class as an evidence-based option [3]. Citing that guideline can strengthen an appeal.

Patients enrolled in Healthy Michigan Plan (the state's Medicaid expansion program) follow the same PA pathway. No separate formulary applies. For dual-eligible beneficiaries (Medicare plus Medicaid), the Medicare Part D plan is the primary payer, and Medicaid may cover residual cost-sharing.

Insurance and Commercial Plan Coverage in Michigan

Most major commercial insurers operating in Michigan place Dayvigo on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position. Blue Cross Blue Shield of Michigan, Priority Health, HAP (Health Alliance Plan), and Molina Healthcare of Michigan all list lemborexant on their 2026 formularies, though tier placement and cost-sharing structures differ by specific plan.

Tier 3 placement typically means a copay of $40 to $75 per month. Tier 4 placement pushes the copay to $75 to $150, or 25% to 40% coinsurance. Step therapy requirements are common. Insurers often require documentation that the patient tried and did not respond to a generic alternative before authorizing coverage of Dayvigo.

A 2023 analysis published in Sleep found that among commercially insured U.S. adults with insomnia, out-of-pocket costs for brand-name DORAs averaged $58 per fill after insurance adjudication, compared with $8 for generic zolpidem [4]. Michigan-specific data tracks closely with those national averages.

For patients on high-deductible health plans (HDHPs), the full negotiated price applies until the deductible is met. In that window, the Eisai savings card becomes especially valuable (see below). Patients with employer-sponsored plans should also check whether their pharmacy benefit carves out to a separate PBM like Express Scripts, CVS Caremark, or OptumRx, as formulary placement can differ from the medical plan's insurer.

Dr. Michael Thorpy, professor of neurology at Albert Einstein College of Medicine, has noted: "Dual orexin receptor antagonists represent a mechanistically distinct approach to insomnia. They block wake-promoting orexin signaling rather than broadly depressing the central nervous system, which translates to a different side-effect profile compared with benzodiazepine receptor agonists" [5].

The Eisai Savings Card: How It Works in Michigan

Eisai, the manufacturer of Dayvigo, offers a copay savings card for commercially insured patients. The program can reduce out-of-pocket costs to as low as $0 per 30-day fill, depending on the patient's insurance plan and the card's annual cap.

Here is how it works. The patient enrolls online or receives a card from the prescriber's office. At the pharmacy counter, the pharmacist runs the patient's primary insurance first, then applies the savings card as a secondary payer to offset any remaining copay or coinsurance. The savings card does not replace insurance. It supplements it.

Key limitations: the Eisai savings card is not valid for patients covered by Medicare, Medicaid, TRICARE, or any other federal or state government-funded healthcare program. This restriction is required by federal anti-kickback statutes. Commercially insured patients in Michigan are eligible as long as their plan does not explicitly exclude manufacturer copay assistance (some accumulator adjustment programs claw back the value of copay cards and do not apply them toward the deductible or out-of-pocket maximum).

Patients should confirm with their insurer whether the plan uses a copay accumulator or copay maximizer program. If it does, the savings card payment will not count toward the annual deductible, which can leave patients exposed to higher costs later in the plan year. The Eisai patient support line can help patients manage these scenarios.

Compounded Lemborexant in Michigan: Legality and Access

Compounded lemborexant is available in Michigan through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on a valid patient-specific prescription, provided the pharmacy meets certain conditions: the drug is compounded by or under the direct supervision of a licensed pharmacist, it is compounded for an individually identified patient based on a prescription, and the pharmacy does not compound regularly or in inordinate amounts [6].

Michigan's Board of Pharmacy regulates compounding under the Michigan Public Health Code. 503A pharmacies operating in the state must hold a valid Michigan pharmacy license and comply with USP General Chapters, including USP <795> for nonsterile compounding.

Cost is a major differentiator. Some Michigan 503A pharmacies offer compounded lemborexant capsules at significantly reduced prices compared to the brand product. However, patients and prescribers should weigh several factors before choosing a compounded version.

Compounded drugs are not FDA-approved and do not undergo the same premarket review for safety, efficacy, and manufacturing consistency as commercially manufactured products. The FDA has stated that compounded drugs "can serve an important role for patients whose medical needs cannot be met by an FDA-approved drug" but emphasizes that they "are not FDA-approved" and "may not meet federal standards for safety, effectiveness, and quality" [7]. For patients considering this route, verifying the compounding pharmacy's accreditation (such as PCAB accreditation) and asking about third-party potency testing adds a layer of quality assurance.

Telehealth Prescribing of Dayvigo in Michigan

Michigan permits telehealth prescribing of Dayvigo. The state's telehealth parity laws, expanded during the COVID-19 public health emergency and made permanent through subsequent legislation, allow licensed prescribers to evaluate patients and issue prescriptions via synchronous audio-video visits. Lemborexant is not a controlled substance under the federal Controlled Substances Act. It is a prescription-only medication but not a Schedule II through V drug, so it does not face the additional DEA telehealth prescribing restrictions that apply to controlled substances.

This means a Michigan-licensed physician, nurse practitioner, or physician assistant can prescribe Dayvigo after a telehealth consultation without requiring an in-person visit. Several national telehealth platforms and Michigan-based health systems offer insomnia evaluations remotely. The prescription can be sent electronically to any Michigan retail or mail-order pharmacy.

Telehealth access matters for patients in rural Michigan counties where sleep medicine specialists are scarce. A study published in the Journal of Clinical Sleep Medicine found that counties in the lowest quartile of sleep specialist density had 40% lower utilization rates of DORA medications, suggesting that access barriers, not clinical need, drive prescribing gaps [8]. Telehealth helps close that gap.

Discount Programs and Additional Savings Strategies

Beyond the Eisai savings card, Michigan residents have several avenues to reduce Dayvigo costs.

Prescription discount platforms. GoodRx, RxSaver, and SingleCare aggregate negotiated pharmacy prices and offer free discount codes. These are especially useful for uninsured patients and can bring the price close to or below the $85 average cash-pay price at participating Michigan pharmacies.

Patient assistance programs (PAPs). Eisai operates a patient assistance program for uninsured or underinsured patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level). Approved patients may receive Dayvigo at no cost. Application requires documentation of income and a prescription from a licensed prescriber.

Pharmacy shopping. Prices for the same drug at the same dose can vary by $30 or more between pharmacies within the same Michigan city. Checking prices at Costco (membership not required for pharmacy in Michigan), Walmart, Kroger, Meijer, and independent pharmacies before filling can yield meaningful savings.

90-day fills. Some insurance plans and discount programs offer a per-unit discount for 90-day supplies versus monthly fills. Mail-order pharmacies through PBMs like Express Scripts or CVS Caremark commonly support 90-day fills at a reduced rate.

Therapeutic alternatives. If cost remains prohibitive, prescribers may consider suvorexant (Belsomra), the other FDA-approved DORA. While suvorexant is also a brand-name product, its pricing and formulary placement may differ from lemborexant on a given patient's plan. The SUNRISE-2 trial, a 12-month study (N=949), demonstrated sustained efficacy of lemborexant on subjective sleep onset and maintenance measures versus placebo, with a safety profile consistent with the DORA class [9]. Discussing trial data with the prescriber helps inform whether switching is clinically appropriate.

The Endocrine Society and AASM both emphasize that insomnia pharmacotherapy should be part of a broader treatment plan that includes cognitive behavioral therapy for insomnia (CBT-I) as the first-line intervention [10]. Dr. Sabra Abbott, assistant professor of neurology at Northwestern University Feinberg School of Medicine, has stated: "CBT-I should be offered to every patient with chronic insomnia. Medications like the DORAs are most effective when used alongside behavioral strategies, not as standalone treatment" [11].

Comparing Dayvigo to Generic Sleep Aids on Cost

The price difference between Dayvigo and generic alternatives is substantial. Generic zolpidem (immediate-release) costs $4 to $15 per month at most Michigan pharmacies. Generic trazodone, often used off-label for insomnia, costs $4 to $10 per month. Generic suvorexant is not yet available (Belsomra's patent protections remain in effect through the mid-2020s).

That cost gap is the primary reason insurers require step therapy. From a payer perspective, demonstrating that lower-cost agents failed or are contraindicated before approving a $85 to $320 per month brand product is standard utilization management.

From a clinical perspective, the mechanisms differ. Zolpidem and other Z-drugs act on GABA-A receptors, producing sedation that can carry risks of complex sleep behaviors (sleepwalking, sleep-driving), next-morning impairment, and dependence with prolonged use. The FDA added a boxed warning to Z-drugs in 2019 due to reports of serious injuries and deaths from complex sleep behaviors [12]. Lemborexant, as a DORA, works by blocking orexin neuropeptides that promote wakefulness. The SUNRISE-1 trial reported the most common adverse events with lemborexant were somnolence (10% at 10 mg vs. 1% placebo) and headache [2]. No boxed warning applies to lemborexant's label.

For patients who have tolerated and responded to generic sleep aids, switching to Dayvigo purely for mechanism may not be cost-justified. For patients with contraindications to GABA-A agonists, a history of complex sleep behaviors, or inadequate response to first-line agents, the DORA class offers a clinically distinct option, and the cost discussion shifts to which access pathway minimizes out-of-pocket burden.

Michigan patients filling a new Dayvigo prescription should request a prior authorization from their prescriber on the same day the prescription is written, apply for the Eisai savings card before the first fill, and compare prices at three or more pharmacies using a discount platform to identify the lowest available rate.